After selling compounded GLP-1 drugs for two years, Hims is launching an expensive shift to branded treatments.
Hims enters a “strategic pivot” following blowback from its copycat Wegovy pill
After selling compounded GLP-1 drugs for two years, Hims is launching an expensive shift to branded treatments.